Search Result

Results for "

Aβ aggregation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (155) 11β-HSD (3) 17β-HSD (1) Adrenergic Receptor (1) Akt (4) AMPK (3) Amylases (1) Amylin Receptor (2) Androgen Receptor (1) Apoptosis (27) Autophagy (7) Bacterial (6) Bcl-2 Family (1) Beta-secretase (8) Biochemical Assay Reagents (2) Calcium Channel (2) Caspase (3) Cholinesterase (ChE) (81) Claudin (1) COX (4) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) Drug Derivative (1) DYRK (1) Endogenous Metabolite (5) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (1) Environmental Pollutants (1) ERK (5) Estrogen Receptor/ERR (7) Factor Xa (1) FAP (1) Ferroptosis (7) Fluorescent Dye (4) Fungal (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (1) Gap Junction Protein (1) Glucocorticoid Receptor (1) Glutathione Peroxidase (2) Glutathione Reductase (GR) (1) GSK-3 (9) HDAC (2) Heme Oxygenase (HO) (2) Histamine Receptor (1) Histone Demethylase (1) Histone Methyltransferase (1) HIV (1) HSP (1) iGluR (2) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Influenza Virus (3) Integrin (8) Interleukin Related (6) Isotope-Labeled Compounds (6) JNK (4) Keap1-Nrf2 (6) KMO (2) Lactate Dehydrogenase (1) Lipoxygenase (1) Microtubule/Tubulin (6) Mitochondrial Metabolism (2) MMP (1) Monoamine Oxidase (16) mTOR (1) nAChR (1) Natriuretic Peptide Receptor (NPR) (1) NF-κB (5) NO Synthase (2) NOD-like Receptor (NLR) (7) p38 MAPK (10) PANoptosis (1) Parasite (1) PARP (2) Photosensitizer (2) PI3K (3) Platelet-activating Factor Receptor (PAFR) (1) Pregnane X Receptor (PXR) (1) Prion Protein (1) Prostaglandin Receptor (4) Pyroptosis (1) Reactive Oxygen Species (ROS) (23) Reference Standards (14) ROS Kinase (3) SARS-CoV (8) Sirtuin (1) SOD (1) Src (1) STING (2) Syk (1) Tau Protein (14) TGF-β Receptor (2) TNF Receptor (3) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1) Transthyretin (TTR) (1) Trk Receptor (1) VEGFR (2) Wnt (3) α-synuclein (10) β-catenin (3) β-glucuronidase (2)
By Research Areas:	Cancer (30) Cardiovascular Disease (21) Infection (15) Inflammation/Immunology (30) Metabolic Disease (18) Neurological Disease (204)
Click Chemistry:	Alkynes (3)

243

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0214

Acid Red 94 sodium 1 Publications Verification	Influenza Virus Photosensitizer Amyloid-β	Infection Neurological Disease Cancer
Acid Red 94 sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research .

HY-N0373

Licochalcone B Maximum Cited Publications 12 Publications Verification	Amyloid-β Apoptosis NOD-like Receptor (NLR)	Neurological Disease
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-12662

PE859 2 Publications Verification	Microtubule/Tubulin	Neurological Disease
PE859 is a potent inhibitor of both tau and Aβ aggregation with IC₅₀ values of 0.66 and 1.2 μM, respectively.

HY-153430

*Aβ/tau aggregation-IN-3*	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-3 is a potent amyloid protein aggregation inhibitor with an IC₅₀ of 0.85 μM by Aβ-Thioflavin T (Aβ-ThT) functional aggregation assay. Aβ/tau aggregation-IN-3 has anti-amyloid activity .

HY-152073

BETA-1	Fluorescent Dye	Others
BETA-1 is the first twisted intramolecular charge transfer (TICT)-aggregation-induced emission (AIE) integration molecule. BETA-1 emits cyan fluorescence in lipid droplets (LDs) and red fluorescence in mitochondria. BETA-1 can be used for the simultaneous and dual-color imaging of LDs and mitochondria in vivo and in vitro .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-W117986

*Aβ aggregation-IN-1*	Amyloid-β Reactive Oxygen Species (ROS) Caspase	Neurological Disease
Aβ aggregation-IN-1 (Compound 1b) is a *β-amyloid* aggregation inhibitor/depolymerizer, with IC₅₀ values of 3.92 μM and 7.19 μM, respectively. Aβ aggregation-IN-1 inhibits the activation of preformed *β-amyloid* fibrils, reactive oxygen species (ROS) and Caspase-3. Aβ aggregation-IN-1 can be used in research related to Alzheimer's disease .

HY-14503

MDR-1339 DWK-1339	Amyloid-β	Neurological Disease
MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-150003

*Aβ1–42 aggregation* inhibitor 1**	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1-42 aggregation inhibitor 1 inhibits AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) with the IC₅₀ value of 2.64 μM and 1.29 μM, respectively. Aβ1-42 aggregation inhibitor 1 inhibits self-mediated Aβ1-42 aggregation by 51.29% at a concentration of 25 μM. Aβ1-42 aggregation inhibitor 1 has the potential for the research of anti-Alzheimer's disease .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-159083

DN5355	Amyloid-β	Neurological Disease
DN5355 is a small molecule compound that targets amyloid β protein (Aβ) and hyperphosphorylated tau protein. DN5355 can inhibit the aggregation of Aβ and tau protein and disaggregate the formed Aβ and tau protein fibers. DN5355 can be used in the study of Alzheimer's disease .

HY-141661

*Aβ/tau aggregation-IN-1*	Amyloid-β	Neurological Disease
Aβ/tau aggregation-IN-1 is a potent Aβ_1-42 β-sheets formation and tau aggregation inhibitor. The K_D values of Aβ/tau aggregation-IN-1 with Aβ_1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier .

HY-114508

Dihydrochalcone 3-Phenylpropiophenone; β-Phenylpropiophenone	Amyloid-β	Neurological Disease
Dihydrochalcone (3-Phenylpropiophenone) is a Aβ aggregation inhibitor. Dihydrochalcone destabilizes Aβ17-42 protofibrils by disrupting the β-sheet of β1 region. Dihydrochalcone destabilizes both U-shaped Aβ40/Aβ42 protofibrils and S-shaped Aβ42 protofibrils by binding to the protofibril cavity. Dihydrochalcone is the main component of daemonorops draco tree .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-121815

TDI-2760	Amyloid-β	Neurological Disease
TDI-2760 is an Aβ aggregation inhibitor with an IC₅₀ of 1.67 μM. TDI-2760 can inhibit the Aβ-fibrinogen interaction and Aβ aggregation, and also modulate the contact system activation induced by Aβ42. TDI-2760 can be used in research related to vascular abnormalities and Aβ aggregation in Alzheimer's disease .

HY-177854

*Aβ aggregation-IN-4*	Amyloid-β	Neurological Disease
Aβ aggregation-IN-4 can alleviate the neurotoxicity of amyloid-β protein (Aβ) and significantly reduce the level of oligomeric complexes of Aβ (Aβ-OCs). Aβ aggregation-IN-4 does not decrease the level of amyloid-β protein (Aβ). Aβ aggregation-IN-4 attenuates Aβ oligomerization and prevents oligomer-induced death of primary cortical neurons. Aβ aggregation-IN-4 can be used for the study of Alzheimer’s disease (AD) .

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-148495

Carnosine conjugated hyalyronate	Amyloid-β	Neurological Disease
Carnosine conjugated hyalyronate is a hyaluronic acid derivative functionalized with the dipeptide carnosine (Carnosine, Car) and has the ability to resist Aβ amyloid aggregation. Carnosine conjugated hyalyronate dissolves amyloid fibrils and reduces Aβ-induced toxicity in vitro. The effectiveness of Carnosine conjugated hyalyronate against amyloid aggregation is directly proportional to the Carnosine loading .

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-144389

hAChE/Aβ1-42-IN-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
hAChE/Aβ1-42-IN-1 (Compound 16) is a potent inhibitor of hAChE and Aβ1-42 aggregation. hAChE/Aβ1-42-IN-1 shows acceptable relative safety upon hepG2 cell line and excellent BBB penetration with wide safety margin. hAChE/Aβ1-42-IN-1 has the potential for the research of Alzheimer disease (AD) .

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-115650

TAE-1	Cholinesterase (ChE) Amyloid-β	Neurological Disease
TAE-1 is a potent inhibitor of AChE and BuChE. TAE-1 also inhibits Aβ fibril formation and aggregation. TAE-1 can be used for the researches of Alzheimer's disease .

HY-149764

Aβ42 agonist-2	Amyloid-β	Neurological Disease
Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells .

HY-149340

PD07	Cholinesterase (ChE)	Neurological Disease
PD07 is an orally active AChE inhibitor (IC₅₀: 0.29 μM for hAChE). PD07 also inhibits ChEs, BACE1 (IC₅₀: 13.42 μM), and Aβ_1–42 aggregation in in vitro. PD07 is an antioxidant, and shows DPPH inhibitory activity (IC₅₀: 26.46 μM). PD07 improves memory and cognition in Scopolamine (HY-N0296)-induced amnesia rats. PD07 can be used for research of Alzheimer’s disease .

HY-119292

AP2238	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with K_i values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease .

HY-13325

*Aβ aggregation* modulator-1**	Drug Derivative Amyloid-β	Neurological Disease
Aβ aggregation modulator-1 is a stimulator of *amyloid-β* (Aβ) fibrillogenesis. Aβ aggregation modulator-1 binds hydrophobic residues in Aβ peptides and stabilizes β-sheet-rich protofibrils and fibrils. Aβ aggregation modulator-1 accelerates Aβ polymerization and reduces concentrations of small, toxic Aβ oligomers in heterogeneous aggregation reactions. Aβ aggregation modulator-1 suppresses long-term potentiation (LTP) inhibition by Aβ oligomers in hippocampal brain slices. Aβ aggregation modulator-1 can be used for the study of Alzheimer's disease (AD) .

HY-173621

*Aβ1–42 aggregation* inhibitor 3**	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC₅₀ values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ_1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research .

HY-149272

*tau/Aβ40 aggregation-IN-1*	Tau Protein Amyloid-β Cholinesterase (ChE)	Neurological Disease
tau/Aβ40 aggregation-IN-1 (Compound 20) is a tau and Aβ₄₀ aggregation inhibitor with IC₅₀s of 1.8 μM and 1.3 μM, respectively .

HY-P5968A

[Ala28]-β Amyloid(25-35) TFA β(25-35)KA TFA	Amyloid-β	Neurological Disease
[Ala28]-β Amyloid(25-35) (β(25-35)KA) TFA is an electrically neutral mutant peptide of Aβ(25-35) that accelerates the aggregation of Firefly Luciferase .

HY-162093

*Aβ1–42 aggregation* inhibitor 2**	Amyloid-β	Neurological Disease
Aβ1–42 aggregation inhibitor 2 (compound 7c) is a potent inhibitor of Aβ1-42 aggregation that plays an important role in Alzheimer's disease research. Aβ1–42 aggregation inhibitor 2 displays excellent antioxidant, metal ions chelating, oxidative stress alleviation, neuroprotective and anti-neuroinflammatory activities .

HY-W265961

Squoxin ST1859; 1,1′-Methylenedi-2-naphthol	Amyloid-β	Neurological Disease Inflammation/Immunology
Squoxin (ST1859) is an antiamyloid agent that specifically binds to Aβ1-42 and prevents the aggregation and fibril formation of Aβ. Squoxin crosses the blood-brain barrier (BBB) and has anthelmintic activity and anti-inflammatory properties .

HY-144324

AChE-IN-6	Cholinesterase (ChE)	Neurological Disease
AChE-IN-6 (Compound 12a) is an optimal multifunctional ligand with significant inhibition of AChE (EeAChE, IC₅₀ = 0.20 μM; HuAChE, IC₅₀ = 37.02 nM) and anti-Aβ activity (IC₅₀ = 1.92 μM for self-induced Aβ1-42 aggregation; IC₅₀ = 1.80 μM for disaggregation of Aβ1-42 fibrils; IC₅₀ = 2.18 μM for Cu2+-induced Aβ1-42 aggregation; IC₅₀ = 1.17 μM for disaggregation of Cu2+-induced Aβ1-42 fibrils). AChE-IN-6 has the potential for the research of Alzheimer's disease .

HY-134894A

Glycerophosphorylethanolamine sodium GroPEtn sodium	Amyloid-β	Neurological Disease
Glycerophosphorylethanolamine (GroPEtn) sodium is an active phosphodiester metabolite of Phosphatidylethanolamine. Glycerophosphorylethanolamine sodium promotes the aggregation of amyloid β-protein (Aβ (1-40)) in vitro. Glycerophosphorylethanolamine sodium can be used in the field of neurodegenerative diseases, such as Alzheimer’s disease research .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P1051

β-Amyloid (12-28) Amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-N8218

Homoeriodictyol 7-O-β-D-glucoside	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activating factor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC₅₀ of 0.8 μM .

HY-N2898

Artanin	Cholinesterase (ChE)	Neurological Disease
Artanin is a coumarin, has biological activities related to Alzheimer’s disease. Artanin exerts function including AChE inhibitory and AChE- and self-induced amyloid beta (Aβ) aggregation inhibitory activities, with IC₅₀s of 51 μM, 98 μM, and 124 μM, respectively .

HY-123745

*Aβ aggregation-IN-6*		Neurological Disease
Aβ aggregation-IN-6 (compound 4) is an Aβ aggregation inhibitor with ~60-70% inhibition of Aβ_17-40 aggregation. Aβ aggregation-IN-6 stabilizes Aβ dimer assembly, binds to Aβ steric-zipper assembly, and interferes with aggregation into higher-order toxic species. Aβ aggregation-IN-6 can be used for the research of alzheimer's disease .

HY-149583

Aβ-IN-8	Amyloid-β	Neurological Disease
Aβ-IN-8 (compound 7e) is a potent inhibitor of the Aβ aggregation .

HY-149582

Aβ-IN-7	Amyloid-β	Neurological Disease
Aβ-IN-7 (compound 5a) is a potent inhibitor of the Aβ aggregation. Aβ-IN-7 with 50 μM stabilize Aβ monomers in the small oligomeric species and prolong the nucleation process. Aβ-IN-7 inhibits Aβ fibril formation better than Aβ-IN-8 (HY-149583) in 50 μM .

HY-174272

GSK-3β inhibitor 27	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive *GSK-3β* inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-147938

AChE-IN-19	Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE-IN-19 (compound A15) is a highly potent AChE inhibitor with an IC₅₀ value of 0.56 μM, also inhibits Aβ aggregation. AChE-IN-19 has potent neuroprotective activities and nearly no toxicity on SH-SY5Y cells. AChE-IN-19 can be used for researching Alzheimer's disease .

HY-155305

BuChE-IN-9	Cholinesterase (ChE) Beta-secretase GABA Receptor	Neurological Disease
BuChE-IN-9 (compound 22a) is a potent equine serum-derived BuChE (eqBuChE) inhibitor with an IC₅₀ of 173 nM. BuChE-IN-9 also inhibits human BACE1, Aβ aggregation, mouse GABA transporter 1 (mGAT1) and mGAT4. BuChE-IN-9 has significant antiamnesic properties .

HY-150585

BuChE-IN-5	Amyloid-β Cholinesterase (ChE) Tau Protein	Neurological Disease
BuChE-IN-5 (compound 25b) is a potent BuChE inhibitor with an IC₅₀ value of 1.94 μM. BuChE-IN-5 efficiently inhibits aggregation Aβ and tau protein in Escherichia coli. BuChE-IN-5 also has free radical scavenging capacity and antioxidant activity. BuChE-IN-5 can be used for researching Alzheimer’s disease .

HY-180160

*Aβ aggregation-IN-3*	Amyloid-β	Neurological Disease
Aβ aggregation-IN-3 (Compound B7) is an Aβ aggregation inhibitor. Aβ aggregation-IN-3 inhibits Aβ aggregation. Aβ aggregation-IN-3 confers protection in both neuronal and microglial models. Aβ aggregation-IN-3 reduces Aβ-induced paralysis in C. elegans. Aβ aggregation-IN-3 improves Alzheimer's disease .

HY-180997

*Aβ aggregation-IN-5*	Amyloid-β	Neurological Disease
Aβ aggregation-IN-5 is a brain-penetrant *amyloid-β* aggregation inhibitor. Aβ aggregation-IN-5 inhibits Aβ aggregation/oligomerization, rescues cells from AB/ROS toxicity and reduces microglial activation/NO production. Aβ aggregation-IN-5 reduces amyloid burden, neuroinflammation, microglial activation in APP/PSEN1 mice. Aβ aggregation-IN-5 can be used for the research of Alzheimer's disease .

HY-173282

*Aβ aggregation-IN-2*	Amyloid-β	Neurological Disease
Aβ aggregation-IN-2 (Compound 8i) is an inhibitor of amyloid-β protein (Aβ42) aggregation, showing approximately 91% inhibition of Aβ42 aggregation at 25 μM. It also exhibits Aβ42 disaggregation effects and antioxidant activity. Aβ aggregation-IN-2 can be used for research in the field of Alzheimer's disease .

HY-147859

BChE-IN-8	Amyloid-β	Neurological Disease
BChE-IN-8 (compound 20) is an orally active, potent and BBB-penetrated BChE (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.15 nM (eqBChE, equine serum BChE) and 45.2 nM (hBChE), respectively. High stability of BChE-IN-8 contributes to significantly improved blood concentration and tissue exposure. BChE-IN-8 can exert neuro-protecting and cognition improving properties through multiple modulations, including cholinergic system, Aβ aggregation, neuropeptide levels. BChE-IN-8 can be used for Alzheimer's disease (AD) research .

Cat. No.	Product Name	Type

HY-D0214

Acid Red 94 sodium

1 Publications Verification

Fluorescent Dye

Acid Red 94 sodium, a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. It is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium holds potential for use in cancer, viral infections, and neurodegenerative disease research .

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Fluorescent Dye

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D2268

QM-FN-SO3	Fluorescent Dye
QM-FN-SO₃ is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

HY-D2268A

QM-FN-SO3 ammonium	Fluorescent Dye
QM-FN-SO₃ ammonium is a BBB-penetrable near-infrared (NIR) aggregation-induced emission (AIE)-active probe for Aβ plaques. QM-FN-SO₃ ammonium can be used for in vivo detection of Aβ plaques. QM-FN-SO₃ ammonium has ultra-high S/N ratio, binding affinity, and high-performance NIR emission .

HY-D0914A

Fast green FCF free acid

Fluorescent Dye

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D0214E

Acid Red 94 sodium (80%)

1 Publications Verification

Fluorescent Dye

Acid Red 94 sodium (80%), a synthetic fluorescein derivative, is a deep red dye primarily composed of 4,5,6,7-tetrachloro-2,4,5,7-tetraiodo fluorescein. Acid Red 94 sodium (80%) is widely used as an ophthalmic diagnostic agent to detect dry or damaged cells on the ocular surface. Acid Red 94 sodium (80%) exhibits antitumor activity and can inhibit Friend Leukemia Virus (FLV) infection through photodynamic action. Additionally, Acid Red 94 sodium (80%) can inhibit Aβ aggregation through light irradiation. Acid Red 94 sodium (80%) holds potential for use in cancer, viral infections, and neurodegenerative disease research .

Cat. No.	Product Name	Type

HY-B2162D

Chondroitin sulfate (from chicken)

Chondroitin polysulfate (from chicken)

Biochemical Assay Reagents

Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and p38MAPK, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE₂. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis .

HY-NP175

Collagen (bovine skin)

Biochemical Assay Reagents

Collagen (bovine skin) is a three-dimensional cell culture matrix and morphoregulator extracted from bovine skin, which binds to integrins (such as α1β1, α2β1, α11β1) and discoidin domain receptors (DDR1 and DDR2). Collagen (bovine skin) can be reconstituted into a three-dimensional fibrous network to mimic the in vivo tissue environment. It can not only be modified through cross-linking or concentration adjustment, but also interact with fibronectin to enhance matrix-associated cellular activities. Collagen (bovine skin) mediates the proliferation, aggregation, durotactic migration and differentiation of fibroblasts, regulates the synthesis, remodeling and contraction of extracellular matrix, and modulates the expression, activation of MMP as well as cell apoptosis, etc. Collagen (bovine skin) can be used in studies related to the mechanisms of cancer occurrence and development .

HY-W012898

Dimethylglyoxime Biacetyl dioxime	Biochemical Assay Reagents
Dimethylglyoxime (Biacetyl dioxime) belongs to the class of oximes and consists of two acetyl groups attached to a nitrogen atom, which in turn is attached to another nitrogen atom through a diimine bond. Dimethylglyoxime is a specific chelator of Ni that inhibits or slows the aggregation of Aβ peptides in vitro .

Cat. No.	Product Name	Target	Research Area

HY-125616

Biotinoyl tripeptide-1 Biotinyl-GHK; Bio-GHK	Amyloid-β Reactive Oxygen Species (ROS)	Neurological Disease
Biotinoyl tripeptide-1 (Biotinyl-GHK) is a biotinylating reagent linked to a GHK (glycyl-L-histidyl-L-lysine) tripeptide. Biotin tripeptide-1 is a bioactive peptide with hair care (improves the appearance and feel of hair) and hair growth effects. Biotinoyl tripeptide-1 has a certain affinity for streptavidin. Biotinoyl tripeptide-1 inhibits the production of ROS and has antioxidant effects. Biotinoyl tripeptide-1 reduces the production of carbonylated *amyloid-β* (Aβ) and inhibits Aβ aggregation. Biotinoyl tripeptide-1 can be used in the study of neurodegenerative diseases .

HY-P1189

Echistatin	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-105066

Davunetide 1 Publications Verification	Microtubule/Tubulin Amyloid-β	Neurological Disease
Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .

HY-P1189A

Echistatin TFA	Integrin	Metabolic Disease Inflammation/Immunology
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-Amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P10578

SEN 304	Amyloid-β	Neurological Disease
SEN 304 is an Aβ aggregation inhibitor. SEN 304 can bind directly to Aβ(1-42), delay β-sheet formation and promote aggregation of toxic oligomers into a nontoxic form. SEN 304 can be used for research of Alzheimer’s disease .

HY-P4886A

Amyloid β-Protein (3-42) TFA	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) TFA is a precursor of Pyr peptide. Pyroglutamic acid-modified Aβ (pEAβ) (3-42) is the core of the amyloid plaque in Alzheimer's disease. pEAβ (3-42) accelerates the aggregation of Aβ(1-42), while Aβ(1-42) significantly slows down the primary and secondary nucleation of pEAβ(3-42).

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P5968A

[Ala28]-β Amyloid(25-35) TFA β(25-35)KA TFA	Amyloid-β	Neurological Disease
[Ala28]-β Amyloid(25-35) (β(25-35)KA) TFA is an electrically neutral mutant peptide of Aβ(25-35) that accelerates the aggregation of Firefly Luciferase .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-P3846

(Glu20)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Glu20)-Amyloid β-Protein (1-42) is a slower fibrillizing variant of amyloid β-protein (Aβ). The Glu20 mutation reduces the aggregation propensity of Aβ42 and prevents accumulation of the slowly fibrillizing peptide. Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease .

HY-P1051

β-Amyloid (12-28) Amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P1388F

FITC-Ahx-β-Amyloid (1-42), (rat/mouse) tris FITC-Ahx-Amyloid β-peptide (1-42) (rat/mouse) tris	Amyloid-β	Neurological Disease
FITC-Ahx-β-Amyloid (1-42), (rat/mouse) (tris) is a fluorescently labeled (FITC) form of β-Amyloid (1-42), (rat/mouse) (HY-P1388), which can be used in Alzheimer's disease-related research, such as aggregation, fiber formation, cellular uptake or imaging experiments. This product is provided in the form of Tris salt.

HY-P10993

CT20p	Bcl-2 Family	Cancer
CT20p is an anticancer peptide based on the C hydrophobic terminus of Bax. CT20p has a unique cytotoxic effect independent of full-length Bax, and can act on mitochondria, leading to fusion-like aggregation and mitochondrial membrane hyperpolarization. CT20p can reduce *α5β1* integrin levels and inhibit F-actin polymerization, thereby destroying the cytoskeleton and preventing cell attachment. CT20p can be used in the study of breast cancer .

HY-P10534

ccβ	Prion Protein	Infection Neurological Disease
CCβ is a simple 17-amino acid peptide designed in research. CCβ is able to mimic the conformational transition of proteins from α-helix to β-sheet, which is a key step in the aggregation of proteins associated with many diseases, such as Alzheimer's disease and prion disease. CCβ can be used to study diseases related to protein aggregation .

HY-P5968

[Ala28]-β Amyloid(25-35) β(25-35)KA	Amyloid-β	Neurological Disease
[Ala28]-β Amyloid(25-35) (β(25-35)KA) is an electrically neutral mutant peptide of Aβ(25-35) that accelerates the aggregation of Firefly Luciferase .

HY-P11231

β4-TAT FUS(364-369)-TAT	Peptides	Cancer
β₄-TAT is a kind of β-sheet peptide foldamer. β₄-TAT is composed of two parts: the β4 sequence (derived from the β-sheet fragment of the RRM domain of fused in sarcoma (FUS)) and the TAT sequence (a nuclear localization signal peptide that helps the entire peptide penetrate the nuclear membrane). β₄-TAT influences FUS aggregation by targeting its RNA recognition motifs (RRM). β4-TAT effectively induces FUS aggregation within cells, leading to the death of cancer cells. β₄-TAT can be used for the study of FUS .

HY-P10037

β Amyloid(17-28) human	Amyloid-β	Neurological Disease
β Amyloid(17-28) human is a β-amyloid peptide (Abeta), a lipid-induced amyloid core fragment. β Amyloid(17-28) human enhances aggregation of full-length β Amyloid40, producing toxic aggregates in Alzheimer's disease (AD) .

HY-P1060

LPYFD-NH2	Amyloid-β	Neurological Disease
LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease .

HY-P3845

(Gly22)-Amyloid β-Protein (1-42)	Amyloid-β	Neurological Disease
(Gly22)-Amyloid β-Protein (1-42) is a peptide fragment of amyloid β-protein (Aβ). Amyloid β-protein is the primary component of both vascular and parenchymal amyloid deposits in Alzheimer's disease. Mutation of Glu22 to Gly22 in Aβ can increase aggregation .

HY-P11384

D-RGDW	Integrin	Cardiovascular Disease
D-RGDW is an Arg-Gly-Asp (RGD) containing peptide. D-RGDW inhibits αIIbβ3 mediated platelet aggregation .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of *amyloid-β* (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P1060A

LPYFD-NH2 TFA	Amyloid-β	Neurological Disease
LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease .

HY-P5370

Scrambled β-amyloid (1-40)	Amyloid-β	Others
Scrambled β-amyloid (1-40) is a biological active peptide. (Aβ (1-40) together with Aβ (1-42) are two major C-terminal variants of the Aβ protein constituting the majority of Aβs. These undergo post-secretory aggregation and deposition in the Alzheimer’s disease brain. This peptide is the scrambled sequence of Abeta 1-40 HY-P0265)

HY-P1051A

β-Amyloid (12-28) TFA Amyloid β-Protein (12-28) TFA; Amyloid Beta-Peptide (12-28) (human) TFA; β-Amyloid protein fragment(12-28) TFA	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (TFA) (Amyloid β-Protein (12-28) (TFA)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) (TFA) shows aggregation properties. β-Amyloid (12-28) (TFA) has the potential for Alzheimer’s disease research .

HY-P4832

Acetyl-Tau Peptide (273-284) amide	Amyloid-β	Neurological Disease
Acetyl-Tau Peptide (273-284) amide is an acetylated Tau peptide fragment. Acetyl-Tau Peptide (273-284) amide limits the substantial aggregation of Ac-Aβ(25–35)-NH2 and can be used as an inhibitor of Ac-Aβ(25–35)-NH2. Acetyl-Tau Peptide (273-284) amide can be used as an experimental model to investigate the Aβ/Tau cross-interaction .

HY-P10824

RI-OR2-TAT	Amyloid-β	Neurological Disease
RI-OR2-TAT is a brain-penetrant inhibitor of *β-Amyloid* oligomerization, which is produced by adding the HIV protein transduction domain TAT to RI-OR2. RI-OR2-TAT binds to Aβ42 fibrils with a K_d value of 58-125 nM. RI-OR2-TAT reduces Aβ aggregation and plaque levels, reduces activation of microglia and oxidative damage, and increases the number of young neurons in the dentate gyrus .

HY-P5340

Amyloid-Forming peptide GNNQQNY	Peptides	Others
Amyloid-Forming peptide GNNQQNY is a biological active peptide. (This is a heptapeptide from the N-terminal prion-determining domain of the yeast protein Sup35 that forms amyloid fibrils. The availability of its detailed atomic oligomeric structure makes it a good model for studying the early stage of aggregation. The GNNQQNY dimer forms three stable sheet structures. in-register parallel, off-register parallel, and anti-parallel. The in-register parallel dimer, which is close to the amyloid beta-sheet structure, has few interpeptide hydrogen bonds, making hydrophobic interactions more important and increasing the conformational entropy compared to the anti-parallel sheet.)

HY-P11677

CPO_Aβ17-21P		Neurological Disease
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC₅₀ of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .

HY-105066R

Davunetide (Standard)	Reference Standards Microtubule/Tubulin Amyloid-β	Neurological Disease
Davunetide (Standard) is the analytical standard of Davunetide (HY-105066). This product is intended for research and analytical applications. Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0570

Hydroxytyrosol 5+ Cited Publications DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol	Infection Structural Classification Canarium album (Lour.) Rauesch. Classification of Application Fields Phenols Polyphenols Plants Endogenous metabolite Burseraceae Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR
Hydroxytyrosol (DOPET; 3,4-Dihydroxyphenethyl alcohol) is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-N0373

Licochalcone B Maximum Cited Publications 12 Publications Verification	Chalcones Flavonoids Leguminosae Plants Glycyrrhiza uralensis Fisch. Source Classification	Amyloid-β Apoptosis NOD-like Receptor (NLR)
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (₄₂) self-aggregation (IC₅₀=2.16 μM) and disaggregate pre-formed Aβ₄₂ fibrils, reduce metal-induced Aβ₄₂ aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-113283

Homogentisic acid	Structural Classification Other disease Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the *Wnt/β-catenin* pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-N7046

Silybin B Silibinin B	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Amyloid-β Apoptosis JNK p38 MAPK
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-N0353

Curdione 2 Publications Verification (+)-Curdione	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Other Diseases Curcuma phaeocaulis Valeton Plants Disease Research Fields Source Classification Zingiberaceae	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting *TGF-β*-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-W010041

Scyllo-Inositol	Natural Products Endogenous metabolite Source Classification	α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and *Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation*, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of *11β-HSD2. Jujuboside B induces ferroptosis* and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N0677

Dehydroandrographolide succinate 1 Publications Verification	Acanthaceae Classification of Application Fields Simsia foetida (Cav.) S.F.Blake Terpenoids Diterpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification Cancer	Influenza Virus Prostaglandin Receptor Akt GSK-3
Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED₅₀ = 386.9 mg/kg) by decreasing TXB₂ levels. Dehydroandrographolide succinate mitigates muscle astrophy via the *Akt/GSK3β* and MuRF-1 pathways .

HY-N2375

L-Quebrachitol	Natural Products other families Classification of Application Fields Metabolic Disease Plants Disease Research Fields Source Classification	Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and *Wnt/β-catenin* signaling pathway .

HY-N6043

Hydroxytyrosol acetate	Structural Classification Canarium album (Lour.) Rauesch. Classification of Application Fields Phenols Polyphenols Plants Burseraceae Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis Reactive Oxygen Species (ROS) Bacterial SARS-CoV Estrogen Receptor/ERR
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-P1189

Echistatin	Natural Products Animals Classification of Application Fields Inflammation/Immunology Disease Research Fields Source Classification	Integrin
Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-W748591

Cannflavin A	Flavonoids Cannabis sativa L Flavones Plants Moraceae Source Classification	Apoptosis Amyloid-β KMO
Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ_1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC₅₀ = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-N1414

(E)-3',6-Disinapoylsucrose	Structural Classification Simple Phenylpropanols Polygalaceae Phenols Polyphenols Phenylpropanoids Plants Polygala tenuifolia Willd. Source Classification	Trk Receptor NF-κB Amyloid-β
(E)-3',6-Disinapoylsucrose is an orally active, blood-brain barrier permeable neuroprotective agent that inhibits Aβ protein aggregation. (E)-3',6-Disinapoylsucrose exerts anxiolytic, anti-inflammatory and cognitive-enhancing effects. (E)-3',6-Disinapoylsucrose regulates the TrkB/BDNF signaling pathway, inhibits the expression of NF-κB p65, reduces pro-inflammatory cytokine levels, and alleviates neuronal damage. (E)-3',6-Disinapoylsucrose also enhances the functions of central 5-HT and noradrenergic systems, thereby improving spatial learning and memory abilities and reducing anxiety-like behaviors. (E)-3',6-Disinapoylsucrose can be used for the research of related diseases such as Alzheimer's disease, depression, memory impairment and anxiety disorder .

HY-P1189A

Echistatin TFA	Natural Products Animals Classification of Application Fields Metabolic Disease Inflammation/Immunology Disease Research Fields Source Classification	Integrin
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of α_IIbβ₃, α_vβ₃ and *α₅β₁* .

HY-121765

Dacisteine N,S-Diacetyl-L-cysteine	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-N0570R

Hydroxytyrosol (Standard) DOPET (Standard); 3,4-Dihydroxyphenethyl alcohol (Standard); 3-Hydroxytyrosol (Standard)	Structural Classification Canarium album (Lour.) Rauesch. Phenols Polyphenols Plants Endogenous metabolite Burseraceae Source Classification	Reference Standards Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR
Hydroxytyrosol (Standard) (DOPET (Standard)) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-N8671

Withanoside V	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	Amyloid-β Apoptosis Reactive Oxygen Species (ROS) SARS-CoV
Withanoside V is a blood-brain barrier-permeable withanolide derivative . Withanoside V binds strongly to Sudlow I (domain IIA) of human serum albumin (HSA) to form a stable complex and alter the secondary structure of albumin, thereby increasing helix content and reducing β-sheet and random coil. Withanoside V binds to Aβ (1-42) to block the interaction between monomers and subsequent aggregation. Withanoside V inhibits the viability of neuroblastoma cells, reduces the number of apoptotic cells induced by Aβ (1-42), and decreases ROS production. Withanoside V inhibits SARS-CoV-2 M_pro. Withanoside V can be used for research on Alzheimer's disease and coronavirus disease 2019 .

HY-W004287

Methyl tridecanoate	Structural Classification Natural Products other families Plants Source Classification	Amyloid-β Cholinesterase (ChE) Parasite
Methyl tridecanoate is a fatty acid methyl ester. Methyl tridecanoate exhibits an IC₅₀ of 3.26 μM and a K_i of 2.30 μM against AsOBP21f in Anopheles sinensis. Methyl tridecanoate induces electroantennographic responses in female Anopheles sinensis. Methyl tridecanoate shows a dose-dependent attractive effect on Anopheles sinensis. Methyl tridecanoate weakly inhibits *β-amyloid* aggregation and AChE activity. Methyl tridecanoate can be used in the research of malaria and Alzheimer's disease .

HY-N9454

Garcinoic acid	Structural Classification Monophenols other families Classification of Application Fields Ketones, Aldehydes, Acids Phenols Plants Disease Research Fields Source Classification Cancer	Pregnane X Receptor (PXR) COX NF-κB Amylases β-glucuronidase DNA/RNA Synthesis Amyloid-β NOD-like Receptor (NLR) Pyroptosis
Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC₅₀=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia .

HY-N8218

Homoeriodictyol 7-O-β-D-glucoside	Cardiovascular Disease Flavonoids Viscum coloratum (Kom.) Nakai Classification of Application Fields Flavonones Phenols Polyphenols Plants Loranthaceae Disease Research Fields Source Classification	Platelet-activating Factor Receptor (PAFR)
Homoeriodictyol 7-O-β-D-glucoside is a natural platelet-activating factor (PAF) antagonist. Homoeriodictyol 7-O-β-D-glucoside inhibits human and rabbit platelet aggregation induced by PAF, with an IC₅₀ of 0.8 μM .

HY-N2898

Artanin	Rutaceae Zanthoxylum nitidum (Roxb.) DC. Coumarins Phenylpropanoids Plants Source Classification	Cholinesterase (ChE)
Artanin is a coumarin, has biological activities related to Alzheimer’s disease. Artanin exerts function including AChE inhibitory and AChE- and self-induced amyloid beta (Aβ) aggregation inhibitory activities, with IC₅₀s of 51 μM, 98 μM, and 124 μM, respectively .

HY-N10183

Crocin-4	Crocus sativus Linn. Iridaceae Terpenoids Diterpenoids Plants Source Classification	Reactive Oxygen Species (ROS)
Crocin-4, a carotenoid constituent of saffron, is a potent and brain-penetrant antioxidant agent. Crocin-4 can inhibit the aggregation and the concomitant deposition of Aβ fibrils in the brain. Crocin-4 can be used for the research of Alzheimer's Disease. Crocin-4 also exhibits antitumor and anti-inflammatory activities .

HY-119398

Lanuginosine	Structural Classification Alkaloids Fissistigma polyanthum (Hook. f. et Thoms.) Merr. Plants Annonaceae Isoquinoline Alkaloids Source Classification	Amyloid-β Cholinesterase (ChE) Apoptosis
Lanuginosine is an alkaloid. Lanuginosine can be isolated from the stems of Xylopia laevigata (Annonaceae) and the leaves of Magnolia grandiflora. Lanuginosine induces Apoptosis. Lanuginosine inhibits AChE (IC₅₀: 10.9 μM). Lanuginosine inhibits Aβ aggregation. Lanuginosine exhibits anticancer activity against hepatocellular carcinoma, human promyelocytic leukemia, human chronic myeloid leukemia, melanoma, and brain tumors. Lanuginosine can be used in the research of Alzheimer's disease .

HY-N8693

Withanoside IV	Structural Classification Withania somnifera Solanaceae Plants Steroids Source Classification	COX Amyloid-β Sirtuin Reactive Oxygen Species (ROS) Apoptosis SARS-CoV
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .

HY-N12067

Columbianetin β-D-glucopyranoside	Plants Umbelliferae Seriphidium transiliense Saccharides Monosaccharides Source Classification	Others
Columbianetin β-D-glucopyranoside can be isolated from Angelicae pubescentis radix and has antiplatelet aggregation, anti-inflammatory and analgesic activities. Columbianetin β-D-glucopyranoside exerts significant protective effects against glutamate-induced toxicity .

HY-N12070

11-O-β-D-glucopyranosyl thamnosmonin	Coumarins Phenylpropanoids Cynara scolymus L. Umbelliferae Plants Source Classification	Others
11-O-β-D-glucopyranosyl thamnosmonin, a coumarin glucosides, can be isolated from the roots of Angelica apaensis. 11-O-β-D-glucopyranosyl thamnosmonin has weak inhibitory activity on the aggregation of rabbit platelets induced by PAF, AA, and ADP .

HY-N9379

Fissistigine A	Alkaloids Structural Classification Monophenols Classification of Application Fields Goniothalamus amuyon (Bl.) Merr. Other Diseases Phenols Plants Annonaceae Isoquinoline Alkaloids Disease Research Fields Source Classification	Others
Fissistigine A is an alkaloid separated of the basic fractions from Formosan Fissistigma glaucescens, F. oldhamii and Goniothalamus amuyon . Fissistigine A has a weak inhibitory effect on amyloid beta 42 aggregation (IC₅₀ 50 µM).

HY-N12321

2',3'-Dihydroxy-4',6'-dimethoxychalcone	Monophenols Labiatae Ulex europaeus L. Phenols Plants Source Classification	Others
2',3'-Dihydroxy-4',6'-dimethoxychalcone (compound 1) can inhibit Amyloid β-protein (Aβ42) fibrillization and aggregation. 2',3'-Dihydroxy-4',6'-dimethoxychalcone has oral activity and can be detected in the brain .

HY-W004287R

Methyl tridecanoate (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Amyloid-β Cholinesterase (ChE)
Methyl tridecanoate (Standard) is the analytical standard of Methyl tridecanoate. This product is intended for research and analytical applications. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE) .

HY-N0373R

Licochalcone B (Standard)	Structural Classification Chalcones Flavonoids Leguminosae Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Source Classification	Reference Standards Amyloid-β Apoptosis NOD-like Receptor (NLR)
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .

HY-W010041R

Scyllo-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards α-synuclein Amyloid-β
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-121765R

Dacisteine (Standard) N,S-Diacetyl-L-cysteine (Standard)	Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less *New Delhi metallo-beta-lactamase-1 (NDM-1)* inhibitor with an IC₅₀ value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .

HY-N2375R

L-Quebrachitol (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Wnt β-catenin p38 MAPK
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .

HY-W748591R

Cannflavin A (Standard)	Flavonoids Cannabis sativa L Flavones Plants Moraceae Source Classification	Amyloid-β Apoptosis Reference Standards KMO
Cannflavin A (Standard) is the analytical standard of Cannflavin A. This product is intended for research and analytical applications. Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ_1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC₅₀ = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line .

HY-N7046R

Silybin B (Standard) Silibinin B (Standard)	Flavanonols Structural Classification Flavonoids Glycine soya Phenols Polyphenols Cyamopsis tetragonoloba (L.) Taub. Plants Compositae Source Classification	Reference Standards JNK Amyloid-β p38 MAPK Apoptosis
Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

HY-N6043R

Hydroxytyrosol acetate (Standard)	Structural Classification Canarium album (Lour.) Rauesch. Phenols Polyphenols Plants Burseraceae Source Classification	Reference Standards Apoptosis Bacterial Reactive Oxygen Species (ROS) SARS-CoV Estrogen Receptor/ERR
Hydroxytyrosol acetate (Standard) is the analytical standard of Hydroxytyrosol (HY-N0570). This product is intended for research and analytical applications. Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Structural Classification Terpenoids Sesquiterpenes Curcuma phaeocaulis Valeton Plants Source Classification Zingiberaceae	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting *TGF-β*-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of *11β-HSD2. Jujuboside B induces ferroptosis* and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-B1588S

Carbenoxolone-d4

Carbenoxolone-d₄ is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties . Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease . Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD . Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop .Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself .

HY-N0570S

Hydroxytyrosol-d4

Hydroxytyrosol-d₄ (DOPET-d₄) is the deuterium labeled Hydroxytyrosol (HY-N0570). Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-N0570S1

Hydroxytyrosol-d5

Hydroxytyrosol-d₅ (DOPET-d5) is the deuterium labeled Hydroxytyrosol (HY-N0570). Hydroxytyrosol is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .

HY-W004287S

Methyl tridecanoate-d25
Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE) .

HY-117259S

Valiltramiprosate-d6

Valiltramiprosate-d₆ (ALZ-801-d₆) is deuterium labeled Valiltramiprosate. ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .

HY-W707693

Scyllo-Inositol-d6

Scyllo-Inositol-d₆ is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .

HY-N7046S

Silybin B-d3

Silybin B-d₃ (Silibinin B-d₃) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .

Cat. No.	Product Name		Classification

HY-179167

K2V-9		Alkynes
K2V-9 is an AChE and MAO-B inhibitor with IC₅₀ values of 1.72 μM and 0.950 μM against AChE and MAO-B, respectively. K2V-9 inhibits amyloid β self-aggregation and reduces ROS. K2V-9 has neuroprotective effects .

HY-146314

MAO-B-IN-9		Alkynes
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent MAO-B (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects . MAO-B-IN-9 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-180114

NSS-18		Alkynes
NSS-18 is a potent and reversible inhibitor of AChE and MAO-B, with IC₅₀ values of 1.53 and 1.51 μM respectively. NSS-18 can inhibit the self-aggregation of Aβ. NSS-18 inhibits the intracellular generation of ROS induced by Aβ. NSS-18 shows a moderate neuroprotective effect against 6-OHDA (HY-B1081)-induced neurotoxicity. NSS-18 can form chelates with metal ions such as Cu²⁺, Fe³⁺, and Zn²⁺, with the strongest chelation being with Cu²⁺. NSS-18 can be used for the study of Alzheimer's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Aβ aggregation

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products